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ABSTRACT
PRODUCTION OF STABLE BCS CLASS II DRUG SUSPENSIONS BY MELT
EMULSIFICATION AND SUBSEQUENT INCORPORATION INTO POLYMER
STRIP FILMS
by
Emanuel Joseph Vizzotti
One of the ways to improve the dissolution rate of poorly water-soluble drugs is to
produce fine drug particles with increased surface area. This increase will lead to
bioavailability enhancement. However, smaller drug particles are thermodynamically
unstable and tend to aggregate or grow. Therefore, proper formulation and process
parameters must be chosen to keep the particles small. In this study, fine drug particles of
two model drugs, fenofibrate and ibuprofen, are prepared by the melt emulsification
technique. The influence of suspension formulation (i.e., the inclusion of polymers and
surface-active agents) on particle stability is investigated. Moreover, different agitation
techniques during cooling are studied for their impact on the physical stability and
recrystallization of molten drug particles. The use of both nonionic surfactant Pluronic
F68 and high-intensity ultrasound during cooling produces fenofibrate and ibuprofen
suspensions with enhanced short-term physical stability. The optimized fenofibrate
suspension is blended with hydroxypropyl methylcellulose film solution and cast into a
solid strip film by oven drying. The film is characterized by redispersion and by
dissolution rate. Particles are recovered from the films in de-ionized water within 5
minutes with no size increase, and a marked increase in dissolution rate is observed in
comparison to as-received particles. The feasibility of incorporating stable drug particles
produced by melt emulsification into strip films and consequent enhancement of particle
recovery and dissolution rate from these films are successfully demonstrated.

PRODUCTION OF STABLE BCS CLASS II DRUG SUSPENSIONS BY MELT
EMULSIFICATION AND SUBSEQUENT INCORPORATION INTO POLYMER
STRIP FILMS

by
Emanuel Joseph Vizzotti

A Thesis
Submitted to the Faculty of
New Jersey Institute of Technology
in Partial Fulfillment of the Requirements for the Degree of
Master of Science in Chemical Engineering
Department of Chemical, Biological, and Pharmaceutical Engineering

May 2013

APPROVAL PAGE
PRODUCTION OF STABLE BCS CLASS II DRUG SUSPENSIONS BY MELT
EMULSIFICATION AND SUBSEQUENT INCORPORATION INTO POLYMER
STRIP FILMS
Emanuel Joseph Vizzotti

Dr. Ecevit A. Bilgili, Thesis Advisor
Date
Assistant Professor of Chemical, Biological, and Pharmaceutical Engineering, NJIT

Dr. Rajesh N. Davé, Thesis Co-Advisor
Date
Distinguished Professor of Chemical, Biological, and Pharmaceutical Engineering, NJIT

Dr. Robert B. Barat, Committee Member
Date
Professor of Chemical, Biological, and Pharmaceutical Engineering, NJIT

BIOGRAPHICAL SKETCH
Author:

Emanuel Joseph Vizzotti

Degree:

Master of Science

Date:May 2013

Undergraduate and Graduate Education:

• Master of Science in Chemical Engineering,
New Jersey Institute of Technology, Newark, NJ, 2013
•

Bachelor of Science in Chemical Engineering,
New Jersey Institute of Technology, Newark, NJ, 2012

Major:Chemical Engineering
Publications:

A. Bhakay, M. Azad, E. Vizzotti , R. N. Davé, E. Bilgili. “Enhanced Recovery and
Dissolution of Griseofulvin N anoparticles from Nanocomposite Microparticles
Incorporating Wet-Milled Superdisi ntegrants. ” Drug Development and Industrial
Pharmacy . 2013, under review.
Poster Presentations:
Vizzotti, E. , A. Bhakay, E. Bilgili, R. N. Davé . “ Production and stabilization of meltemulsified fenofibrate nanoparticles: influence of sonication and additives .” ERC-

SOPS Industrial Advisory Board (IAB) Meeting. 17 January 2013.
Vizzotti, E. , A. Bhakay, E. Bilgili, R. N. Davé . “ Improved drug recovery from oral strip
films carrying recrystallized fenofi brate particles from a melt emulsion process .”

NSF Site Visit. 3 April 2013.

iv

I dedicate my thesis work to my family and many friends, with a boundless feeling of
gratitude to my loving parents, John Vizzotti and Maria Russo, whose words of
encouragement continually ring in my ears. To my sister, Marie, who kept me laughing
the whole journey through.
To Florianna Heun, for putting a smile on my face and keeping my feet on the ground.

v

ACKNOWLEDGMENT

I would like to express my deepest appreciation to my thesis advisor, Dr. Ecevit Bilgili,
whose inspiring tenacity and knowledgeability I will attempt to emulate in my own career
as an engineer, and to my thesis co-advisor, Dr. Rajesh Davé, whose patience knows no
bounds. My special thanks to Dr. Robert Barat for his invaluable advice and active
participation in my committee.
I wish to thank the National Science Foundation and Engineering Research Center
(NSF-ERC) and the New Jersey Institute of Technology for financial support. I am
extremely grateful to Anagha Bhakay, who was my mentor from my first day as a
Research Experience for Undergraduates (REU) student all the way through to the
writing of this thesis, and from whom I learned a lot. I am also thankful for the advice of
my fellow students, Afolawemi Afolabi and Mohammad Azad, which helped shape my
thoughts along the way. I would like to also acknowledge the work of Catharina Knieke,
the shoulders upon which my thesis work stands.

vi

TABLE OF CONTENTS

Chapter

Page

1 INTRODUCTION......................................................................................................

1

1.1 Objective……......................................................................................................

1

1.2 Background……………………………………………………………………..

1

1.2.1 Stability of Drug Particle Suspensions………………………………….

2

1.2.2 Melt Emulsification……………………………………………………..

7

1.3 Problem Definition and General Solution Strategies for ME-based
Suspensions……………………………………………………………………..

9

1.4 Scope and Organization of Thesis………………………………………………

12

2 EXPERIMENTAL SECTION ……………………..……………………………….

13

2.1 Melt Emulsification ...…………………………………………………………..

13

2.2 Polymer Film Production……………………………………………………….

17

3 RESULTS AND DISCUSSION.……………………………………………………

21

3.1 Melt Emulsification ………………………..………………………………...…

21

3.1.1 Effects of Agitation Methods During Cooling.…….…………………....

21

3.1.2 Effects of Additives on Physical Stability……………………………….

29

3.1.3 Effect of Drug……………………………………………………………

33

3.2 Polymer Films Containing Drug Particles ..…………………………………....

35

3.2.1 Redispersion……………………………………………………………..

35

3.2.2 Dissolution……………………………………………………………….

37

4 COMPETITIVE ASSESSMENT…………………………………………………...

40

vii

TABLE OF CONTENTS
(Continued)
Chapter

Page

4.1 Nanoparticle Technology.....................................................................................

40

4.2 Amorphous Particles……………………………………………………………

42

5 CONCLUSIONS…………………………………………………………………….

46

5.1 Melt Emulsification……………………………………………………………..

46

5.2 Polymer Films Containing Drug Particles……………………………………...

47

5.3 Future Work…………………………………………………………………….

47

APPENDIX A INVESTIGATING AMORPHOUS PARTICLE FORMATION ...….

49

A.1 Amorphous Particles in Melt Emulsification…………………………………..

49

A.1.1 Amorphous Particle Production in Solid Dispersion……………………

49

A.1.2 Melt Emulsification of Solid Dispersion………………………………..

50

A.2 Solid Dispersions by Melt-Quench Method for Film Production……………...

51

A.2.1 Experimental Procedure…………………………………………………

52

A.2.2 Assessment of Approach……………………………………………….

53

REFERENCES ………………………………………………………………………...

54

viii

LIST OF TABLES

Table

Page

2.1

Overview of Stabilizers Used in Melt Emulsification……………………………

14

3.1

Fenofibrate Content in Polymer Films……………………………………………

38

ix

LIST OF FIGURES

Figure
1.1

Page

Graphical representation of the physical and chemical stability of nanoparticle
suspensions.……………...………..……………………………………………...

5

2.1

Chemical structures of fenofibrate and ibuprofen…...…………………………...

13

2.2

Experimental setup for the melt emulsification process………………………….

15

2.3

Experimental setup for the film formation process………………………...…….

18

3.1

Effect of using gentle stirring during cooling on particle size and stability ……..

22

3.2

SEM micrograph of FNB particles produced with gentle stirring during cooling.

23

3.3

Effect of using HIU during cooling on particle size and stability………………..

24

3.4

SEM micrograph of FNB particles produced with HIU during cooling………....

24

3.5

Effect of using impeller blade mixing on particle size and stability……………..

26

3.6

Effect of using impeller blade mixing with zirconia beads on particle size and
stability……………………………………………………………………….......

26

3.7

Effect of agitation methods on the cooling rate of emulsions……………………

27

3.8

Effect of ultrasonic intensity on the initial suspension particle size distribution...

28

3.9

Heating curves of FNB particles made with and without sonication during
cooling……………………………………………………………………………

29

3.10 Effect of stabilizer and concentration (wrt drug) on median droplet size…….....

31

3.11 Effect of stabilizer and concentration (wrt drug) on median initial particle size...

31

x

LIST OF FIGURES
(Continued)
Figure

Page

3.12a Effect of HLB value on median droplet size………………………………..

33

3.12b Effect of HLB value on median initial particle size………………………...

33

3.13 Effect of additive and concentration (wrt drug) on median initial particle size
for ibuprofen……………………………………………………………………..

34

3.14 Particle size as a function of time during the film formation process…………...

36

3.15 Effect of stabilization and process conditions for producing FNB
suspensions on the dissolution behavior of polymer strip films………………...
A.1

Heating curves of fenofibrate solid dispersion in PEG 3000 after production
and one week after production…………………………………………………..

A.2

50

Heating curve of filtrate from suspension of FNB solid dispersion processed by
melt emulsification………………………………………………………………

A.3

38

51

Heating curve of film containing FNB particles produced by melt-quench
method……………………………………………………………………….......

xi

52

CHAPTER 1
INTRODUCTION

1.1 Objective
The objectives of this work were to understand the impacts of additive type/concentration
and method of agitation during recrystallization on the short-term stability of fenofibrate
and ibuprofen suspensions produced by the melt emulsification process. The aim was to
then incorporate stable fenofibrate suspensions into the production of polymer strip films
as an attractive solid dosage delivery system and characterize the redispersion and
dissolution behaviors of these films.

1.2 Background
About 90% of the compounds in pharmaceutical delivery pipelines today exhibit poor
water solubility (Page, 2008). This poses a difficulty to the administering of these drugs,
since the human body is made up of 60% water. An active pharmaceutical ingredient
(API) cannot reach its molecular target in the body if the drug remains undissolved in the
gastrointestinal (GI) tract and is ultimately excreted. Simply put, drugs that do not
dissolve cannot heal. In this way, solubilization technologies that overcome this issue
have become increasingly important to the pharmaceutical industry by allowing for the
preparation of effective and commercially viable drugs from actives that would otherwise
be impractical due to solubility limitations. Most poorly water-soluble hydrophobic drugs
belong to a class [Biopharmaceutics Classification System (BCS) Class II] characterized
by limited solubility and dissolution rate, but high permeability through GI membranes
(Amidon et al. 1995).
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There are a number of methods that have been developed to improve drug
solubility and/or dissolution rates. These include: (a) reduction of drug particle size to
increase available surface area for dissolution (Bruno et al. 1996; Merisko-Liversidge et
al. 2003; Bhakay et al. 2011), as per the Noyes-Whitney equation (1897); (b)
manipulation of solid state of drug substance to improve drug dissolution i.e., by
decreasing

crystallinity

of

drug

substance

through

formation

of

solid

solutions/amorphous solids (Zhang et al. 2006; Kim et al. 2008; Shen et al. 2010); (c)
solubilization in surfactant systems (Carvalho et al. 2010); (d) formation of water-soluble
complexes (Jansook et al. 2010); and (e) use of pro-drug and drug derivatives, such as
strong electrolyte salt forms that usually have higher rate of dissolution (Liu et al. 2006).
The implications that come with using the two most popular of these methods (i.e.,
particle size reduction and formation of amorphous solids), including practical
limitations, will be assessed in Chapter 4.

1.2.1 Stability of Drug Particle Suspensions
The

common

physical

stability

issues

related

to

suspensions

include

sedimentation/creaming, aggregation, crystal growth and change of crystallinity state
(Wu et al. 2011). During the storage of suspensions, particle motion exists due to
Brownian motion, convection currents, and sedimentation. Drug particles can either settle
down or cream up in a formulation medium, depending on their density relative to the
medium. The sedimentation rate is described by Stokes' law (Kim, 2004), which
describes the important roles of particle size, medium viscosity, and the density
difference between medium and dispersed phase. When the particles settle, a dense mass
is formed since there is no association between deflocculated particles. Downward

2

movement due to gravity and the lateral motion due to Brownian movement facilitate
tight packing of larger particles with the smaller particles filling the void spaces. Particles
at the bottom of the cake are gradually pressed together by the weight of the ones above.
Decreasing particle size is the most common strategy used to reduce particle settling.
The large surface area of nanoparticles, however, gives rise to high total surface
energy. This is a thermodynamically unfavorable situation, and particles tend to
aggregate in order to minimize their collective surface energy (Merisko-Liversidge et al.
2003). The mechanism of aggregation depends on the density and viscosity of the
suspension medium. In the continuum regime, the particle collisions occur due to
Brownian motion, which describes the random motion of particles suspended in a fluid (a
liquid or a gas) resulting from their bombardment by the fast-moving atoms or molecules
in the gas or liquid (Mörters and Peres, 2008). If there is negligible repulsive force
between the particles, and the collisions result in the irreversible binding of particles and
clusters, the aggregation is called Brownian, since the kinetics of the process are limited
by Brownian diffusion ("Hydrodynamic Parameters of Aggregated Suspensions Formed
from Colloidal Dispersions"). Aggregation can cause a variety of issues for
nanosuspensions including rapid settling/creaming, crystal growth and inconsistent
dosing. The most common strategy used to tackle this issue is the introduction of
stabilizers, the selection of which is based on their ability to provide wetting to surface of
the particles and offer a barrier to prevent nanoparticles from aggregation (Eerdenbrugh
et al. 2008).
A graphical summary of the discussed phenomena associated with suspension
instability, along with a depiction of the stabilization mechanisms discussed, is shown in
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Figure 1.1. There are two main mechanisms through which colloidal suspensions can be
stabilized in suspension media: Electrostatic repulsion and steric stabilization (Kim,
2004; Rabinow, 2004; Nutan and Reddy, 2009). These two mechanisms are achieved by
the addition of ionic and non-ionic stabilizers into the media, respectively. Stabilization
in aqueous media from electrostatic repulsion can be described by the Derjaguin–
Landau–Verwey–Overbeek (DLVO) theory (Derjaguin and Landau, 1941; Verwey,
1947). This theory assumes that the forces acting on colloidal particles in a medium
include repulsive electrostatic forces and attractive van der Waals forces. The repulsive
forces originate from the overlapping of an electrical double layer (EDL) surrounding
particles in a medium, thus preventing colloidal aggregation. As its name implies, the
EDL consist of two layers: (1) a stern layer consisting of counter-ions attracted toward
the particle surface to maintain system electrical neutrality and (2) a Gouy layer, which is
essentially a diffusion layer of ions.
The total potential energy of a particle–particle interaction is the sum of the
repulsion potential generated from EDLs and the attraction potential due to van der
Waals forces (Wu et al. 2011). The attraction potential is determined by the Hamaker
constant, particle size, and inter-particulate distance, while the repulsion potential
depends on particle size, inter-particulate distance, zeta potential, ion concentration and
dielectric constant of the medium. The repulsion potential is extremely sensitive to the
ion concentration in the medium; as the ion strength is increased, the thickness of the
EDL decreases due to screening of the surface charge (Kim, 2004; Nutan and Reddy,
2009). This causes a decrease in the repulsion potential, increasing the susceptibility of
dispersed particles to form aggregates. Zeta potential is the electric potential at the shear
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Figure 1.1 Graphical representation of the physical and chemical stability of
nanoparticle suspensions. The top pictures present various mechanisms associated with
suspension instability; the bottom pictures present methods of promoting suspension
stability.
Edited from source: Wu, L., et al. "Physical and Chemical Stability of Drug
Nanoparticles." Advanced Drug Delivery Reviews. 63.6 (2011): 456-69.

plane—the boundary of the liquid layer surrounding particles in the medium. Zeta
potential is a key parameter widely used to predict suspension stability; the greater the
absolute value of the zeta potential, the more stable the suspension is.
Steric stabilization is usually provided by the utilization of non-ionic stabilizers
like neutral polymers and polymeric surfactants. As these stabilizers hydrate and dissolve
in the suspensions, they begin to adsorb onto the particle surfaces through an anchor
segment that strongly interacts with the dispersed particles, while the well-solvated tail
segment extends into the bulk medium. Non-adsorptive steric stabilization is also a
possible mechanism. As two colloidal particles approach each other, the stabilizing
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segments may interpenetrate, squeezing the bulk medium molecules out of the interparticulate space. This interpenetration is thermodynamically disfavored when a proper
solvent is used as the bulk medium to stabilize the tail (Wu et al. 2011). Accordingly,
provided that the stabilizers can be absorbed onto the particle surface through the anchor
segment, strong enthalpic interaction (good solvation) between the solvent and the
stabilizing segment of the stabilizer is the key factor to achieve steric stabilization and
prevent particles from aggregation in the medium (Kim, 2004; Nutan and Reddy, 2009).
In addition to solvation, the stabilizing moiety (part of the molecule) needs to be
sufficiently long and dense to maintain a steric barrier that is capable of minimizing
particle–particle interaction to a level that the van der Waals attractive forces are less than
the repulsive steric forces (Derjaguin and Landau, 1941; Verwey, 1947; Choi et al. 2005).
It has been shown that combination of both electrostatic and steric stabilization
mechanisms can be very beneficial in achieving stable colloidal suspensions (see Bilgili
and Afolabi, 2012 and references cited therein). In addition, the combination of a nonionic stabilizer with an ionic stabilizer reduces the repulsion between ionic surfactant
molecules, leading to closer packing of the stabilizer molecules (Rabinow, 2004).
Crystal growth in colloidal suspensions is generally known as Ostwald ripening
and is responsible for changes in particle size and size distribution (Voorhees, 1985).
Ostwald ripening is originated from particles solubility dependence on their size; small
particles have higher saturation solubility than larger particles, creating a drug
concentration gradient between the small and large particles. As a consequence,
molecules diffuse from the areas of higher concentration surrounding small particles to
areas around larger particles with lower drug concentration. This diffusion process
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continues until all the small particles are dissolved, essentially making Ostwald ripening
a process where large particles grow at the expense of smaller particles (Wu et al. 2011).
This consequentially leads to a shift in the particle size distribution of a colloidal
suspension to a higher range.

1.2.2 Melt Emulsification
The technique for solubility enhancement that this thesis work focuses on is a particle
engineering method known as melt emulsification (ME). This is a well-known process in
food and pharmaceutical processing literature (Mehnert and Mäder, 2001; Kocbek et al.
2006; Nori et al. 2009; Köhler et al. 2011). To summarize, a suspension containing large
particles is heated to temperatures above the melting point of the disperse phase– in this
case, a drug compound. Since the molten drug is immiscible with the surrounding water,
an oil-in-water (o/w) emulsion is formed. This hot emulsion is exposed to some
mechanical disturbance (e.g., high-intensity ultrasound) that leads to droplet breakup.
Droplet sizes in the nanometer range can be obtained if the applied disturbance is intense
enough. Subsequent cooling of the emulsion eventually leads to the recrystallization of
the oil droplets to solid particles. In this study, fenofibrate (FNB) and ibuprofen (IBU)
were chosen as model poorly water-soluble BCS class II compounds because they exhibit
melting temperatures below the boiling point of water and can thus be emulsified in
aqueous systems. Fenofibrate is known to reduce the cholesterol level in the blood and
exhibits solubility in de-ionized water of just 0.8 mg/L at room temperature (Jamzad and
Fassihi, 2006). The drug can crystallize in two polymorphs, the stable form I (Henry et al.
2003) and the metastable form II (Di Martino et al. 2000). Ibuprofen is a non-steroidal
anti-inﬂammatory drug (NSAID) derivative of propionic acid used widely as an analgesic
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and as an antipyretic, and it is also used for relief of symptoms of rheumatoid arthritis
and osteoarthritis. It exhibits solubility in deionized water of 11.4 mg/L at room
temperature (Garzón and Martínez, 2004). The drug is currently available as a racemic
mixture of S(+)-Ibuprofen and R(−)-Ibuprofen; S(+)-Ibuprofen is the pharmacologically
active form. The racemic mixture is structurally isomorphic and there is no true
crystalline polymorphism (Dudognon et al. 2008).
In pharmaceutical literature, the ME process is well described for the production
of solid-lipid nanoparticles (Mehnert and Mäder, 2001). Another application of the
method allows for the manufacture of ibuprofen nanoparticle suspensions (Kocbek et al.
2006). Emulsification of a hot pre-emulsion was performed in a high pressure
homogenizer at 1000 bar for 5 cycles, followed by rapid cooling in an ice bath. Particle
sizes of 170 nm in a 0.5% (w/w) ibuprofen suspension were obtained with this ME
process using the non-ionic surfactant Tween 80 as a stabilizer. Huang et al. (2009)
investigated the formation of fine FNB powder by another ME process variation. In that
study, emulsification of a hot dispersion was carried out by magnetic stirring in the
presence of Pluronic F127 (10% w/w wrt drug) as a stabilizing agent. The achieved
particle sizes ranged from 1-3 μm with a final suspension solid content of about 2%
(w/w). The suspension was filtered and dried immediately after the solidification step.
Notable improvement to the dissolution behavior was observed for fine FNB powder
when compared to as-received micronized powder (Huang et al. 2009). Li et al. also
studied the ME process with FNB as the model drug. A high pressure homogenizer was
used for emulsification of suspensions with a solid content of 0.5% (w/v). It was shown
that a mixture of polymeric surfactant (Poloxamer 188) and synthetic steric polymer
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(PVP K30) was most ideal for stabilizing the molten droplets. Rapid cooling of the hot
emulsion in an ice bath resulted in particle sizes of about 300 nm, and strong dissolution
rate enhancement was obtained via the produced nanosuspensions. A pharmacokinetic
study in rats revealed greater bioavailability of FNB particles with sizes in the nanometer
range (Li et al. 2009). In a recent study by Knieke et al. (2013b), drug suspensions with
loadings up to 30% (w/w) were produced by a high-intensity ultrasound- (HIU) based
ME process. The particles exhibited median sizes down to 150 nm and did not require
energy inputs as high as other studies have reported. A variety of stabilizers having
different chemical nature were investigated and it was shown that, in general, non-ionic
surfactants perform better than pure polymers in order to achieve smaller particle sizes
(Knieke et al. 2013b). The current study presented here is a continuation of the latter of
these studies.

1.3 Problem Definition and General Solution Strategies for ME-based Suspensions
The physical stability of suspensions produced by an ME process is not reported in
literature. Since disperse systems in general, and suspensions in particular, are unstable in
the thermodynamic sense (Zatz, 1985), one must understand that “physical stability” or,
shortly, "stability" refers to the time-invariance of critical suspension properties (e.g.,
particle size distribution) over some period of time (e.g., 7 days), which may be required
for a specific industrial application. Stability is a critical aspect in ensuring the safety and
efficacy of drug products. Aggregated particles may not dissolve fast enough in vitro and
in vivo, thus somewhat nullifying the effectiveness of producing fine particles via any
particle engineering technique. Similarly, in intravenously administered nanosuspensions,
the formation of larger particles (> 5 μm) could lead to capillary embolism (Patravale et
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al. 2004). Therefore, drug particle size distribution needs to be closely monitored during
storage.
The particle sizes presented in aforementioned ME studies were measured right
after the cooling step (Kocbek et al. 2006; Li et al. 2009; Knieke et al. 2013b); thus,
physical stability of produced suspensions was not investigated. In this thesis, it is shown
that (a) ME-based suspensions can exhibit significant particle size growth during storage
and (b) through proper adjustment of process conditions and selection of additive
type/concentration, enhanced physical stability can be realized.
Applying high-intensity ultrasound to crystallizing systems offers significant
potential for modifying and improving the ME process by enabling proper short-term
stabilization of ME-based suspensions. Although ultrasonics has been used for years in
research and diagnostics, its use in chemical processes has only developed in recent
years. This is because high-intensity systems have become available that can deliver
ultrasonic power on industrially relevant scales (McCausland et al. 2001). The chemical
effects of ultrasound derive primarily from acoustic cavitation. Ultrasound is already
known to influence the crystallization systems in several ways: (1) reduction in induction
time for crystallization; (2) narrowing down crystal size distribution (CSD) with
simultaneous reduction in dominant crystal size; and (3) change in crystal geometry (in
polymorphic systems) (Nalajala and Moholkar, 2011). Studies on organic melts by
Kapustin have shown that ultrasound reduces the time needed for complete crystallization
by a large factor; his results suggest that the mechanism is often simple: the field
produced by ultrasonic cavitation breaks off microcrystals from the growth surface on the
melt, which act as fresh nuclei (Kapustin, 1950; Kapustin, 1952). More recently, studies
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of the so-called sonocrystallization of melts suggest that these effects may be due to small
bubbles produced by high-intensity ultrasonic waves acting as nuclei themselves, or
because fluctuations in the pressure and temperature associated with the ultrasonic wave
disturb the equilibrium between solid and liquid phases (McClements, 1995). Cavitationinduced sonochemistry provides a unique interaction between energy and matter, with hot
spots inside the bubbles of ~5000 K, pressures of ~1000 bar, and heating and cooling
rates of >1010 K s-1 (Bang and Suslick, 2010). These extraordinary conditions permit
access to a range of transport phenomena normally not accessible. It is suggested that the
use of ultrasound during the solidification or cooling step may enhance both the rate of
crystallization from the melt emulsion and the rate at which stabilizer is adsorbed onto
newly-formed particle surfaces.
While the incorporation of particles produced by size-reduction methods into
common solid dosage forms has been investigated appreciably, the integration of those
produced by ME into polymer films remains to be well-studied. Polymer films have great
potential over other dosage forms for delivery of poorly water-soluble drugs. A distinct
advantage is a larger surface area, which leads to rapid disintegration and dissolution in
the oral cavity, resulting in increased bioavailability (Sievens-Figueroa et al. 2012; Beck
et al. 2013). Polymer films are an easily administered dosage form, a fact which has led
to improved acceptability and compliance among geriatric and pediatric patients. This
dosage

form

also

exhibits

manufacturing

advantages,

including

continuous

manufacturing capabilities that enable full product characterization with efficient in-line
monitoring of quality (Dixit and Puthli, 2009). The interest in pharmaceutical films for
oral application has increased based on recent publications and patents (Perumal et al.
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2008; Garsuch and Breitkreutz, 2010; El-Setouhy and Abd El-Malak, 2010; Arya et al.
2010; Bess et al. 2010; R. K. Yang et al. 2010; and Yang et al. 2011). In this thesis, a
variant of the film preparation process outlined in Sievens-Figueroa et al. (2012) is used
to produce polymer films containing dispersed drug particles as the final dosage form for
drug delivery applications. Melt emulsification is used to produce stable fenofibrate and
ibuprofen suspensions; produced fenofibrate suspensions are then transformed into
polymer films.

1.4 Scope and Organization of Thesis
The following chapters outline a study of the melt emulsification process and the
feasibility of its use to produce suspensions of BCS Class II drug particles with enhanced
short-term (i.e., up to one week) stability. Chapter 2 describes the experimental details of
the study, including methods and materials for suspension and film production, as well as
methods for product characterization. Results of the experiments and discussion of these
results are presented in Chapter 3. Chapter 4 is a competitive assessment of the use of
nanoparticle and amorphous particle technologies for solubility enhancement, focusing
on common methods to produce the particles and limitations of the respective
technologies. Finally, Appendix A introduces proof-of-concept experiments for the
investigation of producing amorphous particles in the melt emulsification and polymer
film formation processes.
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CHAPTER 2
EXPERIMENTAL SECTION

This chapter provides an outline of the experimental details of the study presented in this
thesis. It focuses on the methods and materials used for the production of stable BCS
Class II drug suspensions by melt emulsification, the incorporation of suspensions into
polymer strip films, and the characterization of both suspensions and films.

2.1 Melt Emulsification
Materials
Melt emulsification experiments were carried out with the poorly water-soluble drugs
fenofibrate (FNB, Jai Radhe Sales, Ahmedabad, India) and ibuprofen (IBU, Alfa Chem,
NY, USA). The chemical structure of the two drug molecules are shown in Figure 2.1.
FNB has a melting temperature between 78–81 °C; IBU, between 75–78 °C. As-received

Figure 2.1 Chemical structures of fenofibrate (left) and
ibuprofen (right).
drug particles were used in all experiments. To stabilize the droplets in the emulsion, as
well as the particles after solidification, surfactants and polymers were used. All additives
are summarized with their median molecular weight in Table 2.1. In addition, for the
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non-ionic surfactants (Pluronic F68, Pluronic F127, and Tween 80) and the anionic
surfactant sodium dodecyl sulfate, an HLB (hydrophilic-lipophilic-balance) value and
CMC (critical micellar concentration) are listed in the table. The critical micelle
concentration (CMC) is the concentration at which the surfactant molecules saturate
the solution and form micelles upon further addition of surfactant (Feng et al. 2006).

It stands to mention that the CMC values for Pluronics are not well-defined. All
stabilizers were purchased from Sigma Aldrich, with the exception of HPMC E3
(Methocel©, Dow Chemicals, Midland, MI, USA), and were used as-received. Unless
otherwise specified, drug concentrations are weight concentrations with respect to (wrt)
deionized water, whereas the stabilizer concentrations are expressed wrt the drug loading.

Table 2.1 Overview of Stabilizers Used in Melt Emulsification
Stabilizer
Pluronic F68

Abbreviation

HLB
value

Median Molecular
Weight (kDa)

PF 68

29

8,400

CMC
(mM)
a

0.04;
0.9; c~17.9
b
0.5; c3.97
a
0.012
-

b

Pluronic F127
Tween 80
Polyvinylpyrrolidone K30
Hydroxypropyl
Methylcellulose E3
Sodium Dodecyl Sulfate

PF 127
T 80
PVP K30
HPMC E3

22
15
-

12,600
~1,310
40,000
20,300

d

SDS

40

a

288.4

e

8.0

b

Sources: Unless otherwise noted: (Knieke et al. 2013b); Sigma-Aldrich; (Georgieva et al. 2009);
c
(Alexandridis et al. 1994); d(Kawakatsu et al. 1997); e(Dominguez et al. 1997)

Methods
The melt emulsification process is depicted in Figure 2.2 and contains the following
steps: 1) the stabilizer was completely dissolved in deionized water; 2) the as-received
FNB or IBU particles were dispersed in the aqueous solution and the system was heated
to temperatures above the melting point of the drug. To ensure a complete melting and to
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reduce the viscosity of the melt, temperatures at least 10 °C above the melting point of
the drug were attained. Gentle magnetic stirring was applied during the heating process;
3) emulsification was carried out with high-intensity ultrasound by an ultrasonic probe
(Vibra Cell VCX 750, Sonics & Materials, Inc., Newtown, CT) for 5 min at 100%
intensity with a 10s:1s pulse ratio (i.e., a 10 s pulse on, followed by a 1 s pulse off).
During the emulsification step, the system was held at an elevated temperature (10–15°C
above the melting point temperature) to avoid solidification of the melt; 4) Rapid cooling
of the hot emulsion in a thermostatic saline bath at –3.0 °C (NESLAB TRE 10 Digital
One, Thermo Fisher Scientific, Newington, NH) was employed for 10 min, both in the
presence and absence of HIU. Sonocrystallization was carried out with another ultrasonic
probe (Omni Sonic Ruptor 250, Omni, Int’l, Kennesaw, GA) at 50% intensity and a
1.8s:0.2s pulse ratio. In all experiments, the volume of deionized water was 50 ml, and,
unless otherwise noted, a 1% (w/w, wrt DI water) drug suspension was realized.

drug + stabilizer
solution

T > Tmelt

T > Tmelt

Mixing and Heating

Emulsifying

Tbath ≈ -3.0 °C

Figure 2.2 Experimental setup for the melt emulsification process.
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Sample Characterization
Particle size analysis and morphology
Particle size distributions of the FNB suspensions were measured with the laser
diffraction device LS 13 320 (Coulter Beckman, Inc.; Brea, CA, USA) after the
emulsification step, at several time points after the cooling period, during film
production, and upon film redispersion. Samples were added drop-wise until the
polarization intensity differential scattering (PIDS) reached above 40% for all the
samples. Particle size distribution was computed by the software using Mie scattering
theory with a dispersant refractive index of 1.33 and the particle refractive index of 1.546
for FNB and 1.436 for IBU. All particle size distributions presented here are volumeweighted distributions of particle size. Morphological evaluation of the produced
nanoparticles was conducted through scanning electron microscopy (LEO 1530 SVMP,
Carl Zeiss; Peabody, MA, USA). Digital images were obtained at an accelerating voltage
of 2 kV using an InLens detector. The SEM samples were prepared by diluting the
suspensions in de-ionized water and subsequently spreading the dilution onto cleaned Siwafer. The wafers were dried in dust-free conditions in a desiccator and coated with
carbon in the system BAL-TEC MED 020 (BAL-TEC AG; Balzers, Switzerland) to
reduce charging effect during imaging.
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2.2 Polymer Film Production

Materials and Methods
Preparation of films containing nanoparticles
Figure 2.3 shows a schematic of the process used for film formation. A solution
containing 15% HPMC E15 LV (wrt to solution weight) (15 g) and 5% glycerin (wrt to
solution weight) (5 g) was prepared by adding the glycerin to water (80 g) and heating to
80 °C. This composition was chosen in order to ensure a final suspension viscosity and
film quality acceptable for characterization. The polymer was then added until well
dispersed and the temperature was decreased to room temperature to dissolve the polymer
completely. The components were mixed until a transparent, yellowish solution was
obtained. The resulting solution was then let to rest until no bubbles were seen. The
polymer solution (30 g) was then added to the suspension produced from ME (30 g), and
then mixed for 5 h at ~300 rpm using a dual-impeller mixer (McMaster, Catalog no.
3471K5, Los Angeles, CA, USA) attached to a motor (IKA RW16 Basic Overhead
Stirrer) and left to rest until no bubbles were observed. When PF68 was present in the
original drug suspensions, the final FNB film suspensions had 7.5% HPMC, 2.5%
glycerin, 0.493% FNB, and 0.246% PF68. When PF68 was absent from the original drug
suspensions, the final FNB film suspensions had 7.5% HPMC, 2.5% glycerin, and
0.495% FNB. The final viscous suspensions were then casted onto a stainless steel plate
using an Elcometer 3700 Doctor Blade (Elcometer, USA). The wet film thickness was set
to 1000 μm by adjusting the Doctor Blade aperture accordingly. The films were then
dried overnight in an oven (Gallenkamp 300 Plus Series, UK) at 40 °C. The theoretical
amount of drug in the resulting films accounted for either 4.65% (w/w) of the film
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composition (PF68 present) or 4.76% (w/w) of the film composition (PF68 absent),
assuming all of the water had been removed during the drying step.

Figure 2.3 Experimental setup for the film formation process.
Characterization of the ME-based films
The redispersion and dissolution behaviors of four films containing different FNB
suspensions were studied. The suspensions were as follows:
a) As-received, non-processed FNB with no stabilizers
b) FNB with no stabilizers processed in the presence of HIU during cooling
c) FNB stabilized with PF68 in the presence of HIU during cooling
d) FNB stabilized with PF68 in the absence of HIU during cooling
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Assay of Films
Six individual 5.07 cm2 (2.54 cm diameter) circular discs from each film produced were
dissolved in separate 100 ml aqueous solutions of 18.7 mM SDS. The absorbances of 2
ml aliquots from the prepared samples of dissolved FNB were measured at a wavelength
of 290 nm by Ultraviolet (UV) spectroscopy in a UV Spectrophotometer (Evolution 300,
Thermo Scientific; Santa Clara, CA, USA). These six replicates from each film were used
to find the mean drug content in the films. This information, along with the relative
standard deviation, is presented in Table 3.1 of the results and discussion chapter.

Redispersion of Films
Circular samples, 5.07 cm2 (2.54 cm diameter) of each film produced were dispersed in a
50 ml beaker containing 10 ml de-ionized water and stirred magnetically at a speed of
~475 rpm for 5 min. An aliquot of the sample was pulled from the beaker while the
suspension was being stirred and particle size was measured in the LS13320.

Dissolution of Films
Dissolution tests of the produced polymer strip films containing fenofibrate suspensions
were carried out and the results were compared with those of films containing as-received
and non-stabilized drug particles. The dissolution experiments were performed with a
USP type IV apparatus (CE7smart, Sotax; Allschwil, Switzerland) with cells of an
internal diameter of 22.6 mm (Kakhi, 2009; Heng et al. 2008). Films were horizontally
positioned in the cells with 5 g of glass beads (1 mm in diameter) filling up the conical
part at the bottom of each cell. Glass microfiber filters (0.2 µm, GF/D grade) were used
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in the filter-head for each experiment. As a dissolution medium, 600 mL of an 18.7 mM
SDS (above the CMC) solution were used at 37 ± 0.5 °C. Each cell flow rate was set to
16 ml/min. A Thermo Evolution UV spectrophotometer was used to automatically
measure the FNB concentration using a previously made calibration curve. Six samples
were used and the average drug release and standard deviation were plotted as a function
of time. Circular film samples with an area of 1.98 cm2 (1.59 cm diameter) and an
average thickness of 65 μm were used for the dissolution test.

Differential Scanning Calorimetry
Curves of heat flux versus temperature were constructed using DSC (DSC30 using
STARe software, Mettler Instrument, Hightstown, NJ). Samples of filtered suspensions
and final film product (ca. 10 mg) were placed in 40-μL aluminum pans (Mettler
Instrument). An identical empty pan was used as a reference. The samples were scanned
at 10 °C/min with a nitrogen purge. The temperature, time constant, and the heat flow
calibrations for the instrument were performed using indium and zinc.
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CHAPTER 3
RESULTS AND DISCUSSION

3.1 Melt Emulsification
The size of emulsified drug droplets and, hence, drug particles produced by melt
emulsification (ME) depends on the agitation conditions during the emulsification and
cooling steps and the stabilizer type and concentration. Agitation conditions during the
emulsification step were optimized in a prior study (Knieke et al. 2013b), and these
optimum conditions were used throughout the work presented in this thesis. In this way,
the process of preparing fine particles by ME was optimized by variations in the
remaining parameters to achieve stable suspensions.

3.1.1 Effects of Agitation Methods during Cooling
The treatment of emulsions during the cooling step for particle formation was varied to
examine effects on the particle size measured immediately after cooling as well as the
short-term physical stability (i.e., up to one week) of the suspensions. Each formulation
in this section consists of 1 % FNB (w/w) and 0.5 % PF127 (w/w) wrt deionized water.
This formulation was chosen based on optimum low-drug-loading results from Knieke et
al. (2013b). Size distributions are described in terms of D10, D50, and D90, also known
as passing sizes. The D10 value represents the particle size which 10% of the tested
population is smaller than. Similarly, D50 size is larger than the value of 50% of the
tested population, and D90 size is larger than the value of 90% of the tested population.
Figure 3.1 displays the effect of gentle stirring by a metal rod during cooling on the initial
particle size and subsequent particle stability. Immediately after the cooling step, it is
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possible that the drug is still in an amorphous state due to rapid cooling and the
observation of FNB exhibiting high relative glass-forming ability when supercooled from
the molten state (Baird et al. 2010). It has been observed that this so-called supercooled
liquid is very sticky and tends to adhere to other particles and the beaker walls (Knieke et
al. 2013b). As time goes on, the amorphous particles in water may recrystallize. In the
absence of detailed microstructural characterization of the particle samples taken at
different time points, it is hard to suggest when and how such amorphous–crystalline
transition occurs. It is speculated that both supercooled droplets and recrystallized
particles experience coalescence and subsequent particle growth as well as aggregation as
a result of Brownian collisions within an hour while stored at ambient conditions. Indeed,
Figures 3.1 and 3.2 suggest the presence of both large particle aggregates and dendritic
crystal formations (typical of crystal growth).

Particle Size (µm)

100.00
10.00
1.00

D10
D50

0.10

D90

0.01
0 min 5 min 10 min 20 min 30 min 60 min

120
min

1 day

Time Point
Figure 3.1 Effect of using gentle stirring during cooling on particle size and stability.
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Figure 3.2 SEM micrograph of FNB particles produced with
gentle stirring during cooling (30 min after the cooling step).

.

High-intensity ultrasound (HIU), also known as sonication, was employed as a

treatment during the cooling step. Results indicate that particles produced in the presence
of HIU during cooling exhibit enhanced physical stability (i.e., no size increase), even
over the course of 7 days (Figure 3.3). Moreover, after 7 days, the HIU treated sample
showed much smaller particles (Figure 3.3.) than the gentle-stirred sample (Figure 3.1).
The SEM micrograph in Figure 3.4 (Mag. = 30KX) depicts<600 nm primary particles
produced in the presence of HIU during cooling. A comparison of the particle sizes
shown in Figure 3.3 and Figure 3.4 suggests that the particles are somewhat aggregated
even in the HIU treated samples. The larger initial (0 min) particle size distribution, in
comparison with suspensions produced with gentle stirring during cooling, is the result of
more intense agitation during HIU treatment. When HIU is applied to a cooled meltemulsion system, recrystallization is not instantaneous; therefore, there is a greater
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likelihood that soft particles initially collide and aggregate during cooling, before
crystallization and stabilizer adsorption can take place. With the use of HIU, preparation
of ME-based drug suspensions with up to 1-week stability has been successfully
demonstrated.

Particle Size (µm)

100.00
10.00
1.00

D10
D50

0.10

D90

0.01

0 min 5 min 10 min20 min30 min60 min 120 1 day 1
min
week
Time Point
Figure 3.3 Effect of using HIU during cooling on particle size and stability.

Figure 3.4 SEM micrograph of FNB particles produced with
HIU during cooling (30 min after the cooling step).
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During sonication, due to the propagation of ultrasound through water, high and
low pressure cycles are created. Small cavities are generated during the low pressure
cycle that grows in size during further cycles. During the high pressure cycle cavities
collapse creating shock waves and liquid jet streams. This phenomenon, termed as
cavitation, produces transient high local pressures and high temperatures (Sangawar and
Gupta, 2009). Sonication has been used in literature to deagglomerate the agglomerates
(Kusters et al. 1993; Faure et al. 2010) and aggregates (Ding and Pacek, 2008) of
nanoparticles. As the clusters break down and fresh surfaces are exposed, the stabilizers
or additives like surfactants can adsorb to the fresh surfaces and prevent the
reaggregation of the primary particles. If there is no stabilizers or if the stabilizers do not
adsorb to the fresh surfaces fast, the particles can aggregate. It is also observed that when
HIU is applied to an emulsion system undergoing cooling, the temperature was higher
due to higher energy dissipation (to be illustrated in Figure 3.7 below). The presence of
higher temperatures in the emulsified system during cooling may result in (a) faster and
more effective mass transfer of the stabilizer (due to lower suspension viscosity and
higher stabilizer diffusivity) to recrystallized particle surfaces, thus possibly allowing
faster adsorption and (b) preventing the formation of amorphous particles.
Besides HIU, two agitation methods of providing mechanical disturbance were
explored in the hopes of producing stable FNB suspensions:
1. Mixing with a double impeller blade (described in section 2.2) at 1200 RPM
2. Same as (1), with the inclusion of 25 ml of 100 micron yttrium-stabilized zirconia
beads.
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Mixing alone with an impeller blade did not impart physical stability to the
produced suspensions (Figure 3.5). However, with the addition of 100 µm yttriumstabilized zirconia beads, which are used as media in the wet stirred media milling
process, particles remained relatively stable, though particle size distributions achieved
were unfavorably larger than those observed when HIU is used as the agitation method
(Figure 3.6).
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Figure 3.5 Effect of using impeller blade mixing on particle size and stability.
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Figure 3.6 Effect of using impeller blade mixing with zirconia beads on particle size and
stability.
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Figure 3.7 depicts cooling rates for each agitation method used during the cooling
step. Higher temperatures when HIU is employed can be explained as follows. During
HIU, cavitation provides a unique interaction between energy and matter, with hot spots
inside the bubbles of ~5000 K, pressures of ~1000 bar, and heating and cooling rates of
>1000 K s-1 (Bang, J. H. and Suslick, K. S., 2010). Even though these bubbles are very
small, this can have dramatic effect on the rate of heat generated in the emulsion system.
Also, since such intense heat generation is most likely not taking place in systems
exposed to agitation other than HIU, cooling provided by the thermostatic saline bath will
lead to slower decrease in temperature in the HIU treatment as compared with the other
agitation cases.

Figure 3.7 Effect of agitation methods on the cooling rate of emulsions.

The application of HIU during the cooling step was further optimized. A brief
study (Figure 3.8) was carried out to find an optimum intensity specific to the ultrasonic
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probe used in this study. The duration of the ultrasonic treatment was maintained at 10
min (the complete duration of the cooling step).

Particle Size (μm)

100.00

10.00
20%
1.00

50%
70%

0.10

0.01
D10

D50

D90

Figure 3.8 Effect of ultrasonic intensity on the initial suspension particle
size distribution.
It can be argued that the difference between intensities is not very distinct;
nevertheless, given more favorable results in the initial 50% and 90% passing particle
sizes, the 50%-intensity setting was used for the remainder of the study.
In order to confirm the nature of the particles formed during the ME process, DSC
characterization was performed on FNB suspensions stabilized with PF68 and made
either in the presence or absence of HIU during cooling (Figure 3.9). After thirty minutes
of being stored at ambient conditions after the cooling step, the suspensions were syringe
filtered through 0.2 µm filters, and the filtrates were dried at room temperature and
characterized. The presence of endothermic peaks near 80 °C, along with the knowledge
that the only solids in the suspension are the drug particles, confirms the presence of
crystalline FNB particles in both cases. Even if amorphous particles had been produced in
the case where HIU was absent from the cooling step, it is shown that they recrystallized
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within a half hour of the cooling step, due to thermodynamically metastable state of the
amorphous particles. This may not be considered entirely conclusive, however, without
further confirmation with x-ray powder diffraction analysis.

2
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Figure 3.9 DSC thermograms of FNB particles made with and without
sonication during cooling.

3.1.2 Effects of Additives on Physical Stability
Given the optimization of treatment during the cooling step with the addition of HIU, it
was necessary to perform a stabilizer screening study in order to potentially enhance the
stability of FNB suspensions produced by ME. Figures 3.10 and 3.11 depict the effect of
stabilizer type and concentration on the median size of emulsified droplets and initial
particles, respectively. HPMC E3 and PVP K30 are steric polymers. The former is a
cellulosic semi-synthetic polymer; the latter, a synthetic polymer. PF68, PF127, and T80
are non-ionic surfactants, and SDS is an anionic surfactant. At all concentrations, it can
be seen that surfactants as a whole do a better job of maintaining small emulsion droplet
sizes, with T80 performing the best (Figure 3.10). In general, similar behavior was
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observed for the initial median size (Figure 3.11), with PF68 being the best surfactant.
However, at 100% polymer concentration wrt FNB, steric stabilization provided by
HPMC E3 trumps the effects of some surfactants. This is most likely due to solubilization
and subsequent Ostwald ripening of drug particles at concentrations well above these
surfactants’ critical micellar concentrations (CMCs). In some experiments conducted at
high concentrations of the surfactants, including those eventually considered optimized
cases, the surfactants’ CMCs were exceeded.
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Figure 3.10 Effect of stabilizer and its concentration (wrt drug) on
median droplet size.
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Figure 3.11 Effect of additive and its concentration (wrt drug) on
initial median particle size.

Another way to distinguish between surfactant stabilizers is by the use of the
hydrophilic-lipophilic-balance (HLB) concept. The HLB value, first introduced by
Griffin in 1949, is a quantitative measure of the hydrophilic portion in a non-ionic
surfactant. A low HLB number indicates a more lipophilic molecule; a high number, a
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hydrophilic molecule (Davies, 1994). As a consequence, for different emulsion systems
different optimal HLB values exist which are most suitable in stabilizing the produced
droplets (Boyd et al. 1972; Fu et al. 2010). In the case of anionic surfactants, such as
SDS, comparative values have been calculated.
Figures 3.12 (a) and (b) respectively depict the median size of emulsion droplets
and initial particles against the HLB values and concentrations of surfactants used in the
study. The additive concentrations shown on the graphs are wrt drug loading. Figure
3.12a illustrates a general tendency toward an increase in emulsion droplet size for
surfactants with higher HLB. T80, with an HLB value of 15, provides the best emulsion
stability across all concentrations. Studies done following Griffin’s method (Griffin,
1954) suggest that surfactants with HLB values from 12 to 16 are most suitable for
stabilizing o/w emulsions. Furthermore, taking into account relative stability in the
transition from emulsion to suspension, PF68 was the top performing surfactant. It was
observed that suspensions made in the presence of 50% PF68 wrt FNB along with HIU
during cooling exhibited 7-day physical stability (stability result not shown). This was
thus regarded as the optimum case for the incorporation of ME FNB suspensions into
polymer film formation.
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Figure 3.12a and 3.12b Effect of HLB value on droplet
(a) and initial (b) median particle sizes. HLB values for
each surfactant are provided in the adjoining table.

3.1.3 Effect of Drug
The optimization of the agitation method employed during the cooling step of the ME has
been shown. This optimization, along with the knowledge that a screen of available
additives will allow for further optimization of particle size distribution and physical
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stability, was used to investigate the effects of using another candidate drug for the ME
process: ibuprofen.
Figure 3.13 shows a similar trend to the one observed for the stabilizer screen for
the ME of FNB: the use of amphiphilic polymeric surfactants PF68, PF127, and T80
allows for smaller initial particle size in comparison to the pure polymers PVP K30 and
HPMC E3. The nature of these surfactants allows them to not only adsorb on liquid–
liquid interfaces in melt emulsions, but also on particle surfaces upon recrystallization,
providing steric stabilization in both cases (Knieke et al. 2013b). At most additive
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Figure 3.13 Effect of additive and concentration (wrt drug) on the
initial median particle size for ibuprofen.
concentrations wrt drug loading (i.e., 25%, 75%, and 100%), a smaller initial median
particle size was realized with the use of T80. However, at the concentration optimized
for the ME of FNB (50%), PF 68 is once again shown to produce the smallest particles.
Again, it was observed that suspensions made in the presence of PF68 and HIU during
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cooling exhibited 7-day physical stability (results not shown). This leads to the
conclusion that this combination of additive stabilization and agitation during cooling can
be considered an optimum for the ME process presented here, and not just for one
particular drug system.

3.2 Polymer Films Containing Drug Particles
The redispersion and dissolution behaviors of four polymeric films containing FNB
particles processed differently were studied. Processing below refers to the ME process.
These four different films were prepared with
a) As-received, non-processed FNB with no stabilizers (control sample)
b) FNB with no stabilizers processed in the presence of high-intensity ultrasound
(HIU) during cooling
c) FNB stabilized with PF68 in the presence of HIU during cooling
d) FNB stabilized with PF68 in the absence of HIU during cooling
For the remainder of section 3.2, (a), (b), (c), and (d) notation refer to the cases above.
All films had a similar average thickness (~65-70 µm).

3.2.1 Redispersion
In the following figures depicting the redispersion results (Figures 3.14 a, b, c, and d), the
“0 min” size refers to the particle size immediately after the cooling step. In the case of
the as-received particles, this size refers to that measured after mixing 0.5 g of asreceived FNB with 50 ml of DI water for 30 min at ~600 rpm with a magnetic stir bar. In
all cases, the film precursor size was measured after the original suspensions were mixed
with film solution for 5 h to form a so-called film precursor suspension. The redispersion
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particle size was measured after a 5.07 cm2 (2.54 cm diameter) disc of each film
produced was dispersed in a 50 ml beaker containing 10 ml de-ionized water and stirred
magnetically at a speed of ~475 rpm for 5 min. For each size measurement, an aliquot of
the sample was pulled from the container while the suspension was being stirred and
particle size was measured in the LS13320.

Figure 3.14 (a)-(d) Particle size as a function of time during film formation process.
Film (a) contains as-received, non-processed particles; (b) contains ME FNB particles
produced without stabilizers and with HIU during cooling; (c) contains ME FNB
particles produced with both PF68 and HIU during cooling; (d) contains ME FNB
particles produced with PF68 and without HIU during cooling. “0 min” refers to particle
size immediately after mixing (a) or cooling (b-d). “Film Precursor” refers to suspension
after 5 h mixing with polymer film solution. “Redispersion” refers to particles
redispersed from films in deionized water.

As expected, the large as-received FNB particles (a) remained large throughout
the entire film formation process, as large particles were observed upon film redispersion.
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Some size reduction occurred, most likely as a result of the mixing step. Particle
disaggregation is not a typical phenomenon observed during the drying of films; it is
known that colloidal particles confined in liquid films experience attractive capillary
forces, which can cause particle aggregation (Danov et al. 2001). Aggregated particles
produced without additives in the presence of HIU during cooling were recovered in the
redispersion of film (b). The film containing FNB particles produced in the presence of
HIU during cooling and PF68 (c) exhibited smaller sizes due to the prevention of particle
aggregation via steric stabilization. Film containing those particles produced with PF68
and in the absence of HIU during cooling exhibited dramatic particle growth during the
mixing step of the film formation process. Without the enhanced stabilizer adsorption and
crystallization dynamics assumed to exist in the presence of HIU, this lack of physical
stability was to be expected.

3.2.2 Dissolution
The dissolution profiles of the four discussed films, whose redispersion behaviors were
illustrated in Figures 3.14a–d, are depicted in Figure 3.15. The first things to notice are
the considerable error bars associated with the dissolution profiles of films (a) and (b).
These are representations of the poor content uniformity of these films, as made evident
by their respective assays (Table 3.1). The absence of proper stabilization of drug
suspensions and the presence of large particles/aggregates in films (a) and (b) may have
resulted in sedimentation and poor dispersion in the polymer films during drying. The
aggregates have smaller surface area than the constituent fine primary particles, which
explains the slower dissolution of FNB from the films produced in cases (a) and (b). The
smaller variability of the dissolution and faster FNB dissolution associated with the

37

profiles of films (c) and (d) – those made with PF68 – support the fact that proper
additive stabilization in drug suspensions is necessary for reducing the extent of drug
particle aggregation and this producing polymer films homogeneously laden with drug
particles.

Figure 3.15 Effect of stabilization and process conditions for producing FNB
suspensions on the dissolution behavior of polymer strip films.

Table 3.1 FNB Content in Polymer Films

a

Film

Loading of drug
(% w/w)a

Drug content
(% w/w)

a
b

4.76
4.76

1.64±38.14
2.30±21.56

c
d

4.65
4.65

4.56±2.40
4.07±2.27

% w/w is with respect to weight of films after drying.
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The next thing to notice is the fact that films (c) and (d) exhibited almost the same
dissolution behavior. It stands to mention that this has occurred in spite of the fact that
redispersion results show larger particles being released from film (d) than from film (c).
Firstly, as dissolution medium, 600 mL of an 18.7 mM SDS solution were used at 37 ±
0.5 °C; the SDS concentration was higher than the CMC value, which caused an increase
in the solubility of FNB in water. It is possible that the dissolution method has poor
discriminatory power upon use of an SDS solution of this concentration, which was
somewhat required to get detectable assays during the dissolution test. By this reasoning,
however, and the fact that all films studied were of similar thicknesses, films (b) and (d)
should also have similar dissolution profiles, since the redispersion results of these two
films reveal the presence of similarly-sized particles/aggregates. This is not the case,
however. A possible secondary explanation for the indistinguishable nature of the
dissolution profiles of films (c) and (d) may lie in the use of PF68. This polymeric
surfactant, unlike other surfactants, does not have a distinct CMC (Ozturk and Hu, 2005;
Chalmers et al. 2009). In this way it is speculated that PF68 in films (c) and (d) may form
micelles which aid in the solubilization of FNB particles. In conjunction with excess of
surfactant SDS present in the dissolution medium, this may be sufficient to ensure fast
dissolution of FNB particles from polymer strip films.
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CHAPTER 4
COMPETITIVE ASSESSMENT
As expressed in the Introduction, the two classical methods for improving the solubility
of poorly water-soluble drugs are reduction of crystalline particle size and the formation
of the amorphous form of the drug. This chapter serves as a competitive assessment of
these approaches.

4.1 Nanoparticle Technology
Most BCS Class II drugs are characterized by both low equilibrium solubility and a low
dissolution rate, due to high stability of these drugs in the crystalline form. It can be
understood, therefore, that dissolution will not be a fast process, since the drug molecules
are at a preferred energy state. In order to make complete dissolution possible in a time
frame which would allow for increased drug efficacy, the dissolution process should be
fast. Consequentially, increasing the dissolution rate is an effective way to increase the
uptake of a poorly water-soluble drug into the body, enhancing its bioavailability. A
modified version of the previously-mentioned Noyes-Whitney equation (1897) describes
how drug nanoparticles, exhibiting large surface area with small particle sizes, will
enable high dissolution rate and thus bioavailability:

(

)

(4.1)

Here, k0 is the overall solute transfer coefficient defined by 1/k0 = 1/ki + 1/kc, where ki
and kc are the interface rearrangement constant and the external mass transfer coefficient,
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respectively, CS is the saturation solubility, C is the concentration in the bulk solution, A
is the total surface area, and m is the amount dissolved at time t. The major contribution
to the enhanced dissolution rate of the drug is through the increase of both the specific
surface area and the total area A of the particles due to size reduction (Bhakay et al.
2011). Furthermore, if particles are very small (i.e., < 100 nm), solubility can be
described as a function of particle size according to the Kelvin equation (Tadros, 2013):

( )

(

)

In this equation, S(r) is the solubility as a function of the radius r,

(4.2)

is the solubility of a

coarse, crystalline particle, γ is the interfacial tension between drug and solvent, Vm is the
molar volume of the drug, R is the gas constant, and T is the temperature. This equation
clearly shows that solubility increases immensely as the particle size decreases. As a
result of the exponential function, this effect becomes drastic at particle sizes < 100 nm.
The effectiveness of nanoparticle and fine particle suspensions of poorly watersoluble drugs in enhancing bioavailability has been proven in animal models and clinical
trials with various administration routes, including oral, pulmonary, ocular, and
parenteral delivery (Liversidge, G. G., and K. C. Cundy., 1995; W. Yang et al. 2010).
The production of suspensions by particle size reduction has been well-studied at NJIT
using various techniques, including wet stirred media milling (WSMM) (Bhakay et al.
2011; Bilgili and Afolabi, 2012; Monteiro et al. 2013; Knieke et al. 2013a), liquid
antisolvent precipitation (LASP) (Dalvi and Davé, 2009; Beck et al. 2010; Dalvi and
Davé, 2010), rapid expansion of supercritical solutions in a liquid solvent (RESOLV)
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(Dalvi et al. 2013) and melt emulsification (ME) (Knieke et al. 2013b). In addition, drug
suspensions produced by WSMM and LASP have been incorporated into the formation
of polymer strip films for solid dosage forms (Sievens-Figueroa et al. 2012; Beck et al.
2013). In all of the above studies, it has been shown that the dissolution rate of
nanoparticles (particles ≤ 1000 nm in size in prevalent pharmaceutical literature)
resulting from the processing is significantly enhanced in comparison to their as-received,
unprocessed counterparts. The sizes of as-received drug particles are typically on the
order of tens of microns, whereas the resultant suspensions from WSMM, the most robust
of the aforementioned techniques, may contain particles as small as 50–250 nanometers
while maintaining drug loadings up to 30% (w/w) wrt deionized water (Afolabi et al.
2013, under review). In all cases mentioned, the final drug product was confirmed to be
crystalline in nature.

4.2 Amorphous Particles
Several studies have used thermodynamic principles to predict the potential impact of the
amorphous form on bioavailability based on in vitro dissolution profiles and/or thermal
analysis for oral delivery (Hancock and Parks, 2000; Hancock and Zografi, 1997). The
amorphous form of a drug has a higher thermodynamic chemical potential than its
crystalline counterpart (Hilden and Morris, 2004). The higher thermodynamic activity of
the drug can produce supersaturated solutions (Matteucci et al. 2008), thereby providing
an opportunity to enhance absorption and bioavailability. In a study by W. Yang et al.
(2010), the effect of supersaturation on bioavailability of inhaled nebulized aerosols was
compared for amorphous versus crystalline nanoparticulate dispersions. Nanocrystalline
formulations of itraconazole (ITZ), another BCS Class II drug, were made by wet
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milling, whereas amorphous nanostructured aggregates were made by an ultra-rapid
freezing process. Dissolution tests revealed the extent of supersaturation was 4.7-times
higher for the amorphous nanostructured aggregates versus nanocrystalline particles,
though their dissolution rates were similar. However, the increase in the systemic
bioavailability for the amorphous versus crystalline dispersion of about 3.8 times was
approximately the same as the increase in supersaturation measured in vitro in simulated
lung fluid. The high supersaturation, favored by rapid dissolution of amorphous
nanoparticles, prior to particle clearance or crystallization favors high permeability into
the bloodstream. It was concluded that pulmonary delivery of amorphous nanoparticle
formulations of extremely poorly water-soluble drugs is beneficial for both local and
systemic therapy (W. Yang et al. 2010).
Conversely, a study by Meulenaar et al. (2013) reported anomalous dissolution
behavior of amorphous capecitabine, a chemotherapeutic drug belonging to BCS Class
III. These drugs are characterized by their low permeability and high solubility, which are
opposite characteristics from those of Class II drugs. In contrast to what is expected from
thermodynamic theory, amorphous capecitabine dissolved significantly slower in
comparison to its crystalline counterpart. Experiments revealed a “gelling” phenomenon
of amorphous capecitabine in an aqueous environment. The “gel”, which was
immediately formed upon contact with water, entrapped the capecitabine and
significantly slowed down its dissolution. This “gelling” property was hypothesized to be
related to the low glass transition temperature (Tg = 19 °C) of amorphous capecitabine,
resulting in an instant collapse (“gelling”) in an aqueous environment. It was suggested
that this dissolution behavior be applied in the development of a sustained release dosage
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form (Meulenaar et al. 2013). However, in the interest of increasing the dissolution rate
of a drug to prevent its excretion before being therapeutically applicable, it seems that the
production of the amorphous form is not always a clear advantage.
Amorphous APIs are susceptible to recrystallization due to the metastability of
this high-energy state. Therefore, there is a need to physically stabilize them as solid
dispersions in polymeric carriers. Common routes to the production of stable amorphous
state drug particles include quenching of melts (Pokharkar et al. 2006; Lakshman et al.
2008), rapid precipitation by antisolvent addition (Chen et al. 2006; Zhang et al. 2006),
freeze-drying (Pikal, 1994), and spray-drying (Broadhead et al. 1992; Shen et al. 2010).
Amorphous drugs represent opportunity and, in some cases, necessity in
pharmaceutical development. The opportunity arises from the potential to improve
bioavailability via use of an amorphous form, rather than a crystalline form. Challenges
exist in predicting the solubility enhancement ratio of amorphous solids relative to their
crystalline counterparts. These arise due to several factors: (a) a change in
thermodynamic activity of amorphous solute as it absorbs water, (b) in the case of
ionizable compounds in pure water, the difference in degree of ionization of the solute at
different concentrations, and (c) experimentally, onset of crystallization frustrates the
attempt to determine the equilibrium solubility of the amorphous solid (Murdande et al.
2010).
It is sometimes the case that no crystalline form is available, in which case it is
necessary to deal with the amorphous form; cases where this consideration exists include
the use of salts, co-crystals or pharmaceutically-acceptable solvates. The amorphous drug
may be isolated by a variety of methods including precipitation or desolvation of a
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solvate, and the ease of isolation will be affected by the glass transition temperature (T g)
and the extent to which the Tg is lowered by residual solvent (Hancock and Zografi,
1994). In some cases, amorphous salts have been found to have a higher Tg than the free
acid or base (Towler et al. 2008; Tong et al. 2002), and amorphous dispersions may also
be used to improve the physical properties.
In addition, a special interest of this thesis was to investigate the feasibility of
producing amorphous drug particles by means of melt emulsification and the polymer
film formation process. Proof-of-concept experiments are discussed in Appendix A.
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CHAPTER 5
CONCLUSIONS

5.1 Melt Emulsification
The process of preparing stable FNB nanosuspensions by ME was optimized. In general,
the drug nanoparticles produced right after cooling tend to aggregate and grow
significantly during storage. Hence, ensuring the physical stability of the ME-based
suspensions appears to be a challenging task. In this thesis, the effects of different
agitation methods during the cooling step and stabilizer type/concentration on particle
size after cooling and during storage were investigated. The physical stability of the
suspensions was improved when proper mechanical disturbance was applied to the
emulsions during the cooling step via high-intensity ultrasound (HIU). The median
particle size for FNB suspensions produced with HIU during cooling, originally
stabilized using 50% PF127 wrt drug loading, was observed to be between 500–600 nm.
A stabilizer screening study was performed to ensure the optimized use of additives.
Surfactants alone performed more favorably than steric polymers alone in stabilizing both
emulsions and subsequent suspensions. The optimum additive was a polymeric surfactant
PF68 at a concentration of 50% wrt drug loading. This optimization approach was
applied to ibuprofen, another poorly water-soluble drug. The median particle size for
suspensions produced with HIU during cooling and stabilized using 50% PF68 wrt drug
loading, was observed to be between 400–500 nm for FNB and between 1400–1500 nm
for IBU. Combinations of PF68 with pure polymers HPMC E3 or PVP K30 or with T80
(the best emulsifying surfactant) were found to perform less favorably than PF68 alone
(results not shown). FNB suspensions produced in the presence of PF68 and HIU during
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cooling were incorporated into the polymer film production process. The dissolution and
redispersion behaviors of this optimized case were compared to those of films containing
non-optimized suspensions.

5.2 Polymer Films Containing Drug Particles
The effects of particle size, ME conditions during cooling, and additive stabilization on
the redispersion and dissolution behavior of polymer films containing FNB drug particles
were studied. As expected, the film containing non-processed, as-received particles
exhibited recovery of large particles upon redispersion and a poor dissolution profile in
18.7 mM SDS medium. The use of only HIU during cooling to process melt emulsions
was shown to produce a suspension with particle aggregates due to the absence of proper
additive stabilization. The redispersed particle size distribution of this suspension was
similar to that of the suspension produced in the presence of PF 68 and the absence of
HIU, yet the films containing these respective suspensions exhibited very different
dissolution behavior. Furthermore, regardless of a significant difference in redispersed
particle size, both of the films containing particles produced in the presence of PF68
expressed the same dissolution profile. This points to the good stabilizing action of PF68,
in conjunction with the excess SDS (concentration above the CMC) present in the
dissolution medium.

5.3 Future Work
For future work, it is proposed that alternative cooling techniques be investigated for the
production of drug nanosuspensions by ME. The use of cryogenic materials such as
liquid nitrogen may be employed to instantly quench nano-emulsion droplets. This
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technique alone may lead to producing amorphous materials, given the extremely high
degree of expected supercooling. In conjunction with proper application of HIU,
cryogenic cooling may also lead to stable crystalline nanosuspensions with smaller
particle size distributions than the ones observed in this study. In a longer-term study,
other candidate drugs for ME may be further investigated, with careful consideration of
drug crystallization tendencies (Baird et al. 2010).
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APPENDIX A
INVESTIGATING AMORPHOUS PARTICLE FORMATION

Figures A.1 to A.3 depict DSC characterization of particle and film products formed by
the following outlined methods.

A.1 Amorphous Particles in Melt Emulsification
The production of amorphous particles is a topic of great interest in pharmaceutical
research. It has been discussed that these high-energy particles have been shown to
exhibit improved solubility in comparison to their crystalline counterparts. As proof of
concept, an experiment was performed to investigate how particles that are initially
amorphous behave when processed by the melt emulsification technique presented in this
thesis.

A.1.1 Amorphous Particle Production in Solid Dispersion
Amorphous particles of FNB were produced according to the method outlined in
Mahapatra et al. (2010). A solid dispersion of FNB with polyethylene glycol (PEG) 3000,
a hydrophilic polymer, containing a weight ratio of drug and polymer (1:5) was prepared
by melting or fusion method. In this method, an appropriate amount of drug and
hydrophilic polymer was melted in a beaker on a hot plate maintained at a temperature
slightly above the corresponding melting point of the drug. The mixture was cooled
rapidly by placing the beaker in a –3.0 °C bath for about 10 minutes and solidified. The
SD was then ground into smaller particles in a mortar and pestle; this powder was
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immediately characterized by DSC (Figure A.1), and then stored at room temperature
until further study.
The DSC thermograms (without the presence of an endothermic peak at 80 °C
characteristic of crystalline FNB) depicted in Figure A.1 confirms both that amorphous
FNB particles were indeed produced by the solid dispersion and that the particles
remained amorphous after one week. The endothermic peak shown corresponds to the
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melting point of PEG 3000.
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After One Week

Figure A.1 DSC thermograms of fenofibrate solid dispersion in PEG
3000 after production and one week after production.
A.1.2 Melt Emulsification of Solid Dispersion
A 0.5 g of the solid dispersion powder sample was subjected to the optimized ME process
(HIU during cooling and 50% PF68 loading wrt the solid dispersion powder) in a 50 ml
batch. In order to investigate the nature of particles, the produced suspension was syringe
filtered through a 0.2 µm filter thirty minutes after the cooling step. The filtrate was dried
at room temperature and characterized by DSC (Figure A.2). The presence of an
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endothermic peak at 80 °C confirms that particles which were initially amorphous were
recrystallized during the course of the ME process. Given the fact that the particles were
initially amorphous, it is suggested that the ME process presented in this thesis is not
suitable for the production of amorphous particles.
1
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-0.5
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-1.5
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-2.5
Figure A.2 DSC thermogram of filtrate from suspension of FNB solid
dispersion processed by melt emulsification.

A.2 Solid Dispersions by Melt-Quench Method for Film Production
The production of stable amorphous drug particles by solid dispersion in a hydrophilic
polymer matrix has been investigated. Polymer strip films have been discussed as an
attractive solid dosage delivery system. The combination of the two concepts is an
interesting, simple means of producing a solid dosage form infused with drug particles
with enhanced solubility. The details of a proof-of-concept experiment and subsequent
product characterization are presented here.
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A.2.1 Experimental Procedure
0.5 grams of FNB were melted in a beaker with 2.5g of PEG 3000, to maintain
congruence with the ratio of drug to polymer in the solid dispersion experiments. When
complete melting was observed, 50 g of pre-heated polymer film solution (15% HPMC
E15, 5% Glycerin; w/w) was added to the beaker. The system was then subjected to
cooling in a –3.0 °C thermostatic saline bath while being mixed by a dual impeller mixer
at ~300 rpm for 10 minutes. The final temperature of the system was 8 °C. After allowing
for the foam on top of the film suspension to reduce (about five minutes), a film was cast
and dried according to previously described techniques. After drying, the film was
characterized by DSC (Figure A.3) to observe the crystallinity of the embedded FNB
particles.
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Figure A.3 DSC thermogram of film containing FNB particles produced by meltquench method.
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The lack of a distinct endothermic peak at 80 °C suggests that the FNB particles
in the film are at least partially, if not fully, amorphous. Once again, the peak shown
corresponds to the melting point of PEG 3000, just as in the previous solid dispersion
experiment.

A.2.1 Assessment of Approach
The use of this technique allows for the possibility to combine the production of both
amorphous FNB particles and films laden with amorphous particles into a simple meltquench technique. The experiment required minimal equipment– a heating plate, a
cooling bath, and a variable-speed impeller– and resulted in a viscous suspension suitable
for film formation. The final film product seemed homogenously laden with particles
upon observation. This method does not require the use of surfactants which may be
considered unfavorable for consumer dosage formulations. Furthermore, the lack of an
aqueous environment accommodates drugs that have melting temperatures greater than
100 °C; this is a major limitation of the melt emulsification process. Given the simplicity
of the technique and the possibility of creating amorphous particles in a final dosage form
in one step, this concept deserves consideration for future study.
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